Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from GlaxoSmithKline ( (GSK) ).
On 13 February 2026, GSK disclosed that Chief People Officer Diana Conrad acquired American Depositary Shares in the company through a GSK pension plan transaction on the New York Stock Exchange. The purchase, documented in a Form 6-K filed on 25 February 2026 with the U.S. Securities and Exchange Commission, highlights ongoing equity-based participation by senior management, aligning executive interests more closely with GSK shareholders.
The most recent analyst rating on (GSK) stock is a Hold with a $70.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GSK Stock Forecast page.
Spark’s Take on GSK Stock
According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.
The score is supported primarily by resilient fundamentals (strong profitability and positive cash generation) and a constructive earnings outlook with higher dividend guidance and continued specialty/HIV momentum. These positives are tempered by leverage and recent revenue/FCF volatility, while technically the stock is in a strong uptrend but looks overbought, raising near-term pullback risk.
To see Spark’s full report on GSK stock, click here.
More about GlaxoSmithKline
GSK plc is a global biopharma company that focuses on uniting science, technology and talent to get ahead of disease. The U.K.-based group develops and markets innovative medicines and vaccines worldwide, targeting major therapeutic areas and large international healthcare markets.
Average Trading Volume: 4,913,404
Technical Sentiment Signal: Buy
Current Market Cap: $119.9B
See more data about GSK stock on TipRanks’ Stock Analysis page.